This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2011 Jul 28;365(4):285-7.

doi: 10.1056/NEJMp1106689. Epub 2011 Jun 15.

Weighing the benefits of high-dose simvastatin against the risk of myopathy

Amy Egan¹, Eric Colman

Affiliations

Affiliation

¹ Division of Metabolism and Endocrinology Products, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA.

PMID: 21675881
DOI: 10.1056/NEJMp1106689

Weighing the benefits of high-dose simvastatin against the risk of myopathy

Amy Egan et al. N Engl J Med. 2011.

. 2011 Jul 28;365(4):285-7.

doi: 10.1056/NEJMp1106689. Epub 2011 Jun 15.

Authors

Amy Egan¹, Eric Colman

Affiliation

¹ Division of Metabolism and Endocrinology Products, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA.

PMID: 21675881
DOI: 10.1056/NEJMp1106689

No abstract available

PubMed Disclaimer

Similar articles

[Warning for simvastatin 80 mg!].
Olsson AG. Olsson AG. Lakartidningen. 2009 Sep 30-Oct 6;106(40):2549-50. Lakartidningen. 2009. PMID: 19908627 Swedish. No abstract available.
[Lower and lower cholesterol targets increase adverse effects].
Hjemdahl P, Allhammar A, Heaton C, Hulting J, Kahan T, Malmström R, Martinsson A, Rücker F, Schenck-Gustafsson K, Schwieler J, Törnerud M, Wettermark B; Forfattarna utgör Läkemedelssakkunnigas (Läksak) expert-grupp för hjärt-kärlsjukdomar,; Stockholms Iäns landsting. Hjemdahl P, et al. Lakartidningen. 2009 Sep 30-Oct 6;106(40):2550-1. Lakartidningen. 2009. PMID: 19908628 Swedish. No abstract available.
[The last round about statins: there is the fact that 80 mg simvastatin daily results in high risk of myopathy].
Olsson AG. Olsson AG. Lakartidningen. 2009 Oct 21-27;106(43):2783-4; author reply 2784. Lakartidningen. 2009. PMID: 19960911 Swedish. No abstract available.
Does simvastatin cause more myotoxicity compared with other statins?
Backes JM, Howard PA, Ruisinger JF, Moriarty PM. Backes JM, et al. Ann Pharmacother. 2009 Dec;43(12):2012-20. doi: 10.1345/aph.1M410. Epub 2009 Nov 17. Ann Pharmacother. 2009. PMID: 19920157 Review.
New simvastatin dosing recommendations.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2011 Aug 25;53(1370):61-2. Med Lett Drugs Ther. 2011. PMID: 21836544 Review. No abstract available.

See all similar articles

Cited by

What are the benefits and drawbacks of statins in carotid artery disease? A perspective review.
Said S, Dardik A, Ochoa Chaar CI. Said S, et al. Expert Rev Cardiovasc Ther. 2023 Jul-Dec;21(11):763-777. doi: 10.1080/14779072.2023.2286011. Epub 2023 Dec 10. Expert Rev Cardiovasc Ther. 2023. PMID: 37994875 Review.
Mechanistic in vitro studies indicate that the clinical drug-drug interactions between protease inhibitors and rosuvastatin are driven by inhibition of intestinal BCRP and hepatic OATP1B1 with minimal contribution from OATP1B3, NTCP and OAT3.
Elsby R, Coghlan H, Edgerton J, Hodgson D, Outteridge S, Atkinson H. Elsby R, et al. Pharmacol Res Perspect. 2023 Apr;11(2):e01060. doi: 10.1002/prp2.1060. Pharmacol Res Perspect. 2023. PMID: 36811234 Free PMC article.
Abbreviated lipid guidelines for clinical practice : Based on ESC lipid guidelines 2019 and ESC cardiovascular disease prevention in clinical practice guidelines 2021.
Maher V, Gallagher J, Agar R, Griffin D, Colwell N, O'Connor P, McAdam B, Tomkin G, Owens D, Ryan M, Tormey W, Durkan M. Maher V, et al. Ir J Med Sci. 2023 Oct;192(5):2151-2157. doi: 10.1007/s11845-023-03277-x. Epub 2023 Feb 7. Ir J Med Sci. 2023. PMID: 36746882 Free PMC article.
A comprehensive pharmacogenomic study indicates roles for SLCO1B1, ABCG2 and SLCO2B1 in rosuvastatin pharmacokinetics.
Lehtisalo M, Taskinen S, Tarkiainen EK, Neuvonen M, Viinamäki J, Paile-Hyvärinen M, Lilius TO, Tapaninen T, Backman JT, Tornio A, Niemi M. Lehtisalo M, et al. Br J Clin Pharmacol. 2023 Jan;89(1):242-252. doi: 10.1111/bcp.15485. Epub 2022 Aug 22. Br J Clin Pharmacol. 2023. PMID: 35942816 Free PMC article.
Kinome-wide analysis of the effect of statins in colorectal cancer.
Ouahoud S, Jacobs RJ, Peppelenbosch MP, Fühler GM, Heijmans J, Diks S, Wildenberg ME, Hawinkels LJAC, Kodach LL, Voorneveld PW, Hardwick JCH. Ouahoud S, et al. Br J Cancer. 2021 Jun;124(12):1978-1987. doi: 10.1038/s41416-021-01318-9. Epub 2021 Mar 19. Br J Cancer. 2021. PMID: 33742146 Free PMC article.

See all "Cited by" articles

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information